Summit Therapeutics to Report Financial Results for the Third Quarter Ended 31 October 2016 on 15 December 2016
OXFORD, United Kingdom, Dec. 13, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, will be announcing its …